Ultragenyx Files 8-K on Financial Results & Operations
Ticker: RARE · Form: 8-K · Filed: Feb 15, 2024 · CIK: 1515673
| Field | Detail |
|---|---|
| Company | Ultragenyx Pharmaceutical Inc. (RARE) |
| Form Type | 8-K |
| Filed Date | Feb 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, pharmaceuticals, corporate-update
TL;DR
**Ultragenyx just filed an 8-K announcing its financial results and operational condition.**
AI Summary
Ultragenyx Pharmaceutical Inc. filed an 8-K on February 15, 2024, to report on its results of operations and financial condition, along with financial statements and exhibits. The filing, identified by accession number 0000950170-24-015856, indicates the company is providing updated financial information. This standard disclosure was made by the pharmaceutical preparations company, which is incorporated in Delaware and has its business address in Novato, California.
Why It Matters
This filing signals that Ultragenyx Pharmaceutical Inc. is providing updated financial performance and operational status, which is crucial for investors to assess the company's health and future prospects. It ensures transparency and compliance with SEC regulations.
Risk Assessment
Risk Level: low — This 8-K merely announces the reporting of financial results and operations, without disclosing specific positive or negative financial data in the provided text, thus presenting no immediate new risk.
Key Numbers
- N/A — Specific Financial Figures (No specific financial figures or results are detailed in this 8-K snippet, only the announcement of their reporting.)
Key Players & Entities
- Ultragenyx Pharmaceutical Inc. (company) — filer
- February 15, 2024 (date) — date of report
- Novato, California (location) — business address
- Delaware (location) — state of incorporation
FAQ
What is the purpose of this 8-K filing by Ultragenyx Pharmaceutical Inc.?
The purpose of this 8-K filing is to report on the company's "Results of Operations and Financial Condition" and "Financial Statements and Exhibits," as indicated by the Item Information.
When was this 8-K filed and what is the earliest event reported date?
This 8-K was filed as of February 15, 2024, and the date of the earliest event reported is also February 15, 2024.
What is the Standard Industrial Classification (SIC) for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc.'s Standard Industrial Classification is "PHARMACEUTICAL PREPARATIONS [2834]".
Where is Ultragenyx Pharmaceutical Inc.'s principal executive office located?
The principal executive office for Ultragenyx Pharmaceutical Inc. is located at 60 Leveroni Court, Novato, California, 94949.
What is the company's Central Index Key (CIK)?
The Central Index Key (CIK) for Ultragenyx Pharmaceutical Inc. is 0001515673.
Filing Stats: 496 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-02-15 16:04:29
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value RARE Nasdaq Global Select
Filing Documents
- rare-20240215.htm (8-K) — 41KB
- rare-ex99_1.htm (EX-99.1) — 297KB
- img45776771_0.jpg (GRAPHIC) — 7KB
- img45776771_1.jpg (GRAPHIC) — 7KB
- 0000950170-24-015856.txt ( ) — 484KB
- rare-20240215.xsd (EX-101.SCH) — 23KB
- rare-20240215_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 15, 2024, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended December 31, 2023 and the year ended December 31, 2023 (the " Press Release "). A copy of the Press Release is furnished herewith as Exhibit 99.1 The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated February 15, 2024. 104 The cover page from the Company's Current Report on Form 8-K dated February 15, 2024 formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ultragenyx Pharmaceutical Inc. Date: February 15, 2024 By: /s/ Howard Horn Howard Horn Executive Vice President, Chief Financial Officer, Corporate Strategy